New pre-surgery treatment for advanced stomach cancer with immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old.
- You have confirmed stomach adenocarcinoma that is locally advanced and meets specific staging features (Borrmann type III/IV and bulky lymph nodes).
- You have tumors that can be measured on CT or MRI scans.
- Your general health score (ECOG) is 0 or 1, meaning you’re able to do most daily activities.
- You have not had prior stomach cancer surgery or prior anti-cancer chemo, radiation, or immunotherapy.
- On scans and pre-treatment endoscopy, there’s no sign of stomach cancer spread to the lining of the belly (peritoneal metastasis), and no cancer cells in washed-out stomach fluid.
- If you can become pregnant, a pregnancy test must be negative shortly before starting treatment, and you must meet the trial’s criteria to avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial tests giving an immunotherapy drug before surgery to see if it can increase immune cells in the tumor and improve outcomes for people with advanced stomach cancer. It may help shrink the tumor and make surgery more effective.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Hear when a new Immunotherapy Gastrict Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.